Tags

Type your tag names separated by a space and hit enter

Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED.
Am J Emerg Med 2005; 23(7):842-7AJ

Abstract

BACKGROUND

Acute asthma is often treated with racemic albuterol, a 1:1 mixture of (R)-albuterol and (S)-albuterol. Levalbuterol is the single-isomer agent comprised (R)-albuterol, an active bronchodilator, without any effects of (S)-albuterol.

OBJECTIVE

To compare emergency department (ED) admission rates of patients presenting with acute asthma who were treated with either racemic albuterol or levalbuterol.

SETTING

Suburban community teaching hospital.

DESIGN

Retrospective observational case review.

METHODS

Emergency department patients presenting with acute asthma at 2 different sites were reviewed over 9- and 3-month consecutive periods. Outcome measures included ED hospital admission rate, length of stay, arrival acuity, and treatment costs. Patients were excluded if younger than 1 year or if no treatment of acute asthma was rendered.

RESULTS

Of the initial 736 consecutive cases, significantly fewer admissions (4.7% vs 15.1%, respectively; P = .0016) were observed in the levalbuterol vs racemic albuterol group. Of the subsequent 186 consecutive cases, significantly fewer admissions were also observed (13.8% vs 28.9%, respectively; P = .021) in the levalbuterol vs racemic albuterol group. Treatment costs were lower with levalbuterol mainly because of a decrease in hospital admissions.

CONCLUSION

Levalbuterol treatment in the ED for patients with acute asthma resulted in higher patient discharge rates and may be a cost-effective alternative to racemic albuterol.

Authors+Show Affiliations

Summit Medical Group, 80 Division Avenue, Summit, NJ 07901, USA. dschreck@comcast.netNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16291438

Citation

Schreck, David M., and Stephen Babin. "Comparison of Racemic Albuterol and Levalbuterol in the Treatment of Acute Asthma in the ED." The American Journal of Emergency Medicine, vol. 23, no. 7, 2005, pp. 842-7.
Schreck DM, Babin S. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Am J Emerg Med. 2005;23(7):842-7.
Schreck, D. M., & Babin, S. (2005). Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. The American Journal of Emergency Medicine, 23(7), pp. 842-7.
Schreck DM, Babin S. Comparison of Racemic Albuterol and Levalbuterol in the Treatment of Acute Asthma in the ED. Am J Emerg Med. 2005;23(7):842-7. PubMed PMID: 16291438.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. AU - Schreck,David M, AU - Babin,Stephen, PY - 2005/04/08/accepted PY - 2005/11/18/pubmed PY - 2006/1/20/medline PY - 2005/11/18/entrez SP - 842 EP - 7 JF - The American journal of emergency medicine JO - Am J Emerg Med VL - 23 IS - 7 N2 - BACKGROUND: Acute asthma is often treated with racemic albuterol, a 1:1 mixture of (R)-albuterol and (S)-albuterol. Levalbuterol is the single-isomer agent comprised (R)-albuterol, an active bronchodilator, without any effects of (S)-albuterol. OBJECTIVE: To compare emergency department (ED) admission rates of patients presenting with acute asthma who were treated with either racemic albuterol or levalbuterol. SETTING: Suburban community teaching hospital. DESIGN: Retrospective observational case review. METHODS: Emergency department patients presenting with acute asthma at 2 different sites were reviewed over 9- and 3-month consecutive periods. Outcome measures included ED hospital admission rate, length of stay, arrival acuity, and treatment costs. Patients were excluded if younger than 1 year or if no treatment of acute asthma was rendered. RESULTS: Of the initial 736 consecutive cases, significantly fewer admissions (4.7% vs 15.1%, respectively; P = .0016) were observed in the levalbuterol vs racemic albuterol group. Of the subsequent 186 consecutive cases, significantly fewer admissions were also observed (13.8% vs 28.9%, respectively; P = .021) in the levalbuterol vs racemic albuterol group. Treatment costs were lower with levalbuterol mainly because of a decrease in hospital admissions. CONCLUSION: Levalbuterol treatment in the ED for patients with acute asthma resulted in higher patient discharge rates and may be a cost-effective alternative to racemic albuterol. SN - 0735-6757 UR - https://www.unboundmedicine.com/medline/citation/16291438/Comparison_of_racemic_albuterol_and_levalbuterol_in_the_treatment_of_acute_asthma_in_the_ED_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0735-6757(05)00159-2 DB - PRIME DP - Unbound Medicine ER -